… safety concerns, the randomized phase was initiated. Patients were randomly assigned 2:1:…
The primary objectives of the randomized phase were to determine whether vandetanib 300 …

… randomized phase III study showing the advantage of molecularly targeted therapy over
cytotoxic chemotherapy as second-line therapy for non–small cell lung cancer… In phase II studies …

… Based on these observations, we initiated a randomized phase II trial in patients with
advanced non-small-cell lung cancer (NSCLC) in which bevacizumab was combined with …

… in a phase II randomized study of the Spanish Lung Cancer … and active in a phase II
randomized study from our group 35 … trial, 34 and of our randomized phase II trial, 35 we suggest …

… II (randomized, double-blind placebo-controlled) study of the safety, efficacy and PK of … for
treatment-naive extensive-stage small-cell lung cancer patients. Patients received trilaciclib or …

… We conducted this international, randomized phase II trial to prospectively compare the
progression-free survival (PFS) of erlotinib plus tivantinib with erlotinib plus placebo among …

PURPOSE: The local site of relapse in non-small cell lung cancer (NSCLC) is primarily
located in the high FDG uptake region of the primary tumour prior to treatment. A phase II PET-…

… Here, we report the results of a multicenter, open-label, randomized phase II study that
compared the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CXCR4 …

… This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared
… -mutated non–small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768 ). …

… We conducted a prospective randomized phase III trial to compare single-agent pemetrexed
versus the combination of carboplatin and pemetrexed in the first-line management of …